A randomized phase II study of FID-007 Plus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

nanoencapsulated paclitaxel (FID-007) - ANP Technologies, Fulgent Genetics

Erbitux (cetuximab) - Eli Lilly

paclitaxel - Generic mfg.

J. Thomas1; C.H. Chung2; E. Nadler3; D. Richards4; M. Hsieh5; R. Yin5; J.J. Nieva1; G. Rabinowits6

Jul 24, 2025